title: Postsurgical thyroid remnant estimation by (⁹⁹m) Tc-pertechnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma.
abstract: BACKGROUND
  The purpose of this study was to evaluate the relationship between postsurgical neck (⁹⁹m) technetium ((⁹⁹m) Tc)-pertechnetate uptake and the rate of successful remnant ablation after radioiodine treatment in patients with differentiated thyroid carcinoma (DTC).
  
  
  METHODS
  Retrospectively enrolled were 232 patients with DTC who underwent total thyroidectomy and fixed activity ablation with 3.7 GBq ¹³¹I. The (⁹⁹m) Tc scans were performed on all patients before ¹³¹I administration. Thyroid ablation was assessed after 6 to 12 months by thyroid-stimulating hormone (TSH)-stimulated ¹³¹I-WBS and thyroglobulin measurement. The rate of successful ablation, occurrence of radioiodine-induced thyroiditis, and length of hospitalization were correlated with the (⁹⁹m) Tc-pertechnetate scintigraphy results.
  
  
  RESULTS
  A (⁹⁹m) Tc uptake was significantly lower in ablated versus nonablated patients (p < .001). High (⁹⁹m) Tc-pertechnetate uptake, especially greater than 1.4%, predicted a high-risk of unsuccessful ablation. Higher (⁹⁹m) Tc-pertechnetate uptake was also related to prolonged hospitalization and the occurrence of radioiodine-induced thyroiditis.
  
  
  CONCLUSIONS
  The (⁹⁹m) Tc-pertechnetate scintigraphy is a simple and feasible tool to evaluate thyroid remnants and to predict radioiodine ablation results in patients with DTC.
authors.affiliation: Department of Nuclear Medicine, PET-CT Center and Thyroid Unit, Oncology Institute of Southern Switzerland, CH-6500 Bellinzona, Switzerland. luca.giovanella@eoc.ch
authors.forename: Luca
authors.initials: L
authors.lastname: Giovanella
authors.forename: Sergio
authors.initials: S
authors.lastname: Suriano
authors.forename: Riccardo
authors.initials: R
authors.lastname: Ricci
authors.forename: Luca
authors.initials: L
authors.lastname: Ceriani
authors.forename: Frederik
authors.initials: F
authors.lastname: Anton Verburg
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000097:blood / Q000000981:diagnostic imaging* / Q000532:radiotherapy* / Q000601:surgery; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D019275:Radiopharmaceuticals; D013670:Sodium Pertechnetate Tc 99m; D013954:Thyroglobulin / Q000097:blood; D013961:Thyroid Gland / Q000000981:diagnostic imaging*; D013964:Thyroid Neoplasms / Q000097:blood / Q000000981:diagnostic imaging* / Q000532:radiotherapy* / Q000601:surgery; D013965:Thyroidectomy; D013972:Thyrotropin / Q000097:blood; D015899:Tomography, Emission-Computed, Single-Photon; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D013972:Thyrotropin; D013954:Thyroglobulin; D013670:Sodium Pertechnetate Tc 99m